Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Rats and High-Fructose Corn Syrup | Main | Drugs And Their Starting Points »

March 23, 2010

We Don't Know Beans About Biotin

Email This Entry

Posted by Derek

You know, you'd think that we'd understand the way things bind to proteins well enough to be able to explain why biotin sticks so very, very tightly to avidins. That's one of the most impressive binding events in all of biology, short of pushing electrons and forming a solid chemical bond - biotin's stuck in there at femtomolar levels. It's so strong and so reliable that this interaction is the basis for untold numbers of laboratory and commercial assays - just hang a biotin off one thing, expose it to something else that has an avidin (most often streptavidin) coated on it, and it'll stick, or else something is Very Wrong. So we have that all figured out.

Wrong. Turns out that there's a substantial literature given to arguing about just why this binding is so tight. One group holds out for hydrophobic interactions (which seems rather weird to me, considering that biotin's rather polar by most standards). Another group has a hydrogen-bonding explanation, which (on the surface) seems more feasible to me. Now a new paper says that the computational methods applied so far can't handle electrostatic factors well, and that those are the real story.

I'm not going to take a strong position on any of these; I'll keep my head down while the computational catapults launch at each other. But it's definitely worth noting that we apparently can't explain the strongest binding site interaction that we know of. It's the sort of thing that we'd all like to be able to generate at will in our med-chem programs, but how can we do that when we don't even know what's causing it?

Comments (12) + TrackBacks (0) | Category: Drug Assays | In Silico


COMMENTS

1. PharmaHeretic on March 23, 2010 1:51 PM writes...

Link to the last publication does not work.

Permalink to Comment

2. PedroS on March 23, 2010 2:18 PM writes...

The paper is
http://pubs.acs.org/doi/abs/10.1021/ja909575j

Permalink to Comment

3. Wavefunction on March 23, 2010 2:21 PM writes...

Yes, the traditional explanation now is that biotin forms five strong hydrogen bonds by pushing out entropically and enthalpically "unhappy" water molecules from a hydrophobic region. The last link does not work by the way.

Permalink to Comment

4. Sili on March 23, 2010 3:28 PM writes...

To the semi-trained eye it makes some sense, the the stronger the bonding, the harder it is to model. Weak interactions allow all sorts of perturbation approaches, but the stronger something binds the further it must be energetically from the (better understood?) precursors.

Permalink to Comment

5. Hap on March 23, 2010 3:56 PM writes...

Wouldn't that imply that you are likely to miss lots of tight-binding inhibitors by computational methods though? Unless inhibitors use lots of weak interactions to bind tightly, inhibitors that bind tightly aren't going to be found or understood in silico because the interactions that would be occurring wouldn't be modeled well.

Permalink to Comment

6. metaphysician on March 23, 2010 4:11 PM writes...

*cough* Am I the only one who is amused that biotin doesn't contain any tin?

*non-chemist, non-biologist*

Permalink to Comment

7. Sili on March 23, 2010 4:15 PM writes...

I'd certainly expect them to be underestimated, and if you push perturbations too far, they do break down.

BUT I'm not a comp chemist. I've only taken the basic three courses in quantum chemistry at my uni, and that's ... closer and closer to a decade ago, so I may very well be utterly and completely off the mark.

Permalink to Comment

8. hibob on March 23, 2010 5:34 PM writes...

@#5 Hap "Wouldn't that imply that you are likely to miss lots of tight-binding inhibitors by computational methods though? "
Oddly enough, computational methods miss lots of tight-binding inhibitors. Of course, they also miss most of the other inhibitors, some of the ones they do pick up are modeled as binding at the wrong binding site/ or using wrong orientation... and then there are the false positives! Using full non-linear Poisson-Boltzman equations for a big chunk of protein + solvent + other stuff is still non-trivial, I gather.


Permalink to Comment

9. Henning Makholm on March 23, 2010 8:21 PM writes...

#6 methaphysician: Not half as amused as I am by the apparently vital importance of Pb compounds in drug discovery...

*neither*

Permalink to Comment

10. Anonymous on March 23, 2010 10:27 PM writes...

Do not believe in those numerical data. Especially those in the supporting file, energies by residue, non-physical at all.
many of them do not make any sense. wonder how it got published by jacs.

Questions on the paper: (1)How big are the errors from each of the term? need to validate it by trying the same approaches for more experiment data, say HIV mutations, lots of data available. (2)Neutral form for the 2nd molecule with guanidine, kidding? (3)PBSA is not realible for Free energy calculation. check the dielectric constant=1 inside protein, 80 in the solvent, realible results from it? (4)the protein structure with or without ligand would be quite different, and contribute a lot to the binding, little info is available from the paper: only took a complex from pdb, and use the protein for another ligand with some MD. Big Q: what's the global minimum structure for the protein without ligand, how much change in structure and energies?

Permalink to Comment

11. barry on March 24, 2010 12:36 AM writes...

wow, I casually speak as if I "understand" a binding if I've seen an x-ray diffraction structure of the complex, but nothing about the published co-structure 3FDC sets this one apart as extraordinary

Permalink to Comment

12. Pete on March 24, 2010 7:07 AM writes...

I took a quick look at this and found a couple of things that worried me. Apparently in the bound state the cyclic guanidine in 2’-iminobiotin (BTN2) is neutral (i.e. not protonated). I don’t know the pKa of this cyclic guanidine but I would guess that it will high (I seem to recall a figure of 13+ for guanidine itself). This means the free energy that you measure for the binding of BTN2 will reflect the energy cost of converting the cationic (predominant form in solution) guanidinium to the neutral (bound) guanidine. I’m not sure if/how the authors are taking account of this but I suspect that much of a 6 kcal/mol difference in the binding free energies biotin and its imino analogue could be explained by free energy differences between the guanidinium and guanidine forms of BTN2.

The other concern I had was around the SCRF-like calculations. SCRF actually refers to an entire family of solvent models that are available to users of the Gaussian03 electronic structure program but the authors have not indicated which of these their procedure follows. Energies calculated with continuum models like these are sensitive to atomic radii and typically you need to parameterise radii and charge/QM-treatment together since you need larger radii for stronger electrostatics. In addition, nasty things can happen when you’ve got anions (the infamous outlying charge problem) and I am generally wary of physical interpretations of results of calculations like these.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Gitcher SF5 Groups Right Here
Changing A Broken Science System
One and Done
The Latest Protein-Protein Compounds
Professor Fukuyama's Solvent Peaks
Novartis Gets Out of RNAi
Total Synthesis in Flow
Sweet Reason Lands On Its Face